Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543398 | 0.93 | HRH3 (0.40) | MEN1KMT2AHRH3KCNH2HSD17B10 | |
| SCHEMBL28452884 | 0.88 | L3MBTL3 (0.41) | MEN1KMT2AL3MBTL3CYP2D6CYP2C19 | |
| SCHEMBL5429121 | 0.88 | MEN1 (0.41) | MEN1KMT2AHRH3KCNH2HSD17B10 | |
| SCHEMBL3083396 | 0.88 | MEN1 (0.44) | MEN1KMT2AHRH3KCNH2L3MBTL3 | |
| SCHEMBL13632342 | 0.86 | MEN1 (0.43) | MEN1KMT2AHRH3KCNH2HSD17B10 | |
| SCHEMBL13632346 | 0.86 | MEN1 (0.43) | MEN1KMT2AHRH3KCNH2HSD17B10 | |
| SCHEMBL2318967 | 0.86 | MEN1 (0.43) | MEN1KMT2AHRH3KCNH2HSD17B10 | |
| SCHEMBL1306349 | 0.84 | MEN1 (0.44) | MEN1KMT2AL3MBTL3CYP2D6CYP2C19 | |
| SCHEMBL1711612 | 0.82 | MEN1 (0.43) | MEN1KMT2AL3MBTL3CYP2D6CYP2C19 | |
| SCHEMBL24480263 | 0.78 | KMT2A (0.36) | MEN1KMT2AHRH3KCNH2L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045508-A1 | SUBSTITUTED AMINOMETHYL BENZAMIDE COMPOUNDS | HNMT, HRH3, HRH4 | MEN1 1986/4885KMT2A 350/4885HRH3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.